Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

GEBBIA, Nicolo'
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.060
EU - Europa 4.363
AS - Asia 870
AF - Africa 12
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 8
Totale 14.331
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.045
IT - Italia 1.024
FI - Finlandia 882
UA - Ucraina 812
CN - Cina 656
DE - Germania 492
IE - Irlanda 262
SE - Svezia 226
GB - Regno Unito 224
RU - Federazione Russa 143
FR - Francia 89
RO - Romania 60
IN - India 53
KR - Corea 49
BE - Belgio 42
IR - Iran 26
PL - Polonia 21
NL - Olanda 18
ES - Italia 16
GR - Grecia 15
TR - Turchia 14
CA - Canada 12
CH - Svizzera 11
SG - Singapore 9
EU - Europa 8
EG - Egitto 7
HK - Hong Kong 7
JP - Giappone 7
AT - Austria 6
CZ - Repubblica Ceca 6
UZ - Uzbekistan 6
VN - Vietnam 6
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
BR - Brasile 4
LB - Libano 4
MY - Malesia 4
NZ - Nuova Zelanda 4
ID - Indonesia 3
PE - Perù 3
PK - Pakistan 3
BD - Bangladesh 2
BG - Bulgaria 2
CL - Cile 2
IL - Israele 2
LY - Libia 2
MX - Messico 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
ZA - Sudafrica 2
AL - Albania 1
AR - Argentina 1
AZ - Azerbaigian 1
BY - Bielorussia 1
DK - Danimarca 1
HR - Croazia 1
HU - Ungheria 1
IQ - Iraq 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
MK - Macedonia 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
SA - Arabia Saudita 1
Totale 14.331
Salva come PNG Salva come JPEG
Città #
Fairfield 1.243
Chandler 847
Ashburn 784
Woodbridge 720
Wilmington 611
Houston 553
Ann Arbor 539
Seattle 491
Jacksonville 422
Cambridge 386
Dublin 256
Des Moines 230
Palermo 224
Medford 219
Nanjing 150
Princeton 145
Altamura 144
Lawrence 105
Tulsa 102
New York 97
Boardman 88
San Diego 80
Dearborn 74
Beijing 61
Milan 55
Ludwigshafen am Rhein 52
Shenyang 49
Jinan 45
Nanchang 45
Seongnam 45
Hebei 44
Brussels 42
Changsha 41
San Mateo 39
Tianjin 34
Saint Petersburg 31
Jiaxing 30
Helsinki 28
London 27
Kumar 26
Guangzhou 22
Venice 21
Falls Church 20
Zhengzhou 20
Bremen 19
Tehran 18
Los Angeles 17
Ningbo 17
San Paolo di Civitate 17
Verona 17
Auburn Hills 15
Chicago 15
Rome 14
Lanzhou 13
Phoenix 13
Washington 13
Izmir 12
Kilburn 12
Kraków 12
Munich 12
Düsseldorf 10
Hangzhou 10
Moscow 10
Redwood City 10
Kunming 9
Pune 9
Taiyuan 9
Athens 8
Haikou 8
Norwalk 8
Edinburgh 7
Fuzhou 7
Mazara del Vallo 7
Monza 7
Singapore 7
Taizhou 7
Central District 6
Erice 6
Indiana 6
Durham 5
Madrid 5
Orange 5
Polska 5
Prague 5
Toronto 5
Atlanta 4
Florence 4
Mountain View 4
Rho 4
San Francisco 4
Shanghai 4
Taipei 4
Torino 4
Vienna 4
Andover 3
Aversa 3
Detroit 3
Frankfurt Am Main 3
Fremont 3
Hanoi 3
Totale 9.758
Salva come PNG Salva come JPEG
Nome #
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment 276
4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). 260
Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus. 215
Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-inducing activity in HL60 and in MDR Cell lines 199
The role of histamine in doxorubicin and teniposide-induced cardiotoxicity in dog and mouse 197
Stilbene-based anticancer agents: Resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism. 193
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features 188
Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells 183
Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy 182
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma 174
EGFR genomic alterations in cancer: prognostic and predictive values 174
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. 171
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients 164
Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. 163
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer 161
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses. 161
Anti-endothelin drugs in solid tumors 161
Studies on the apoptotic activity of natural and synthetic retinoids: discovery of a new class of synthetic terphenyls that potently support cell growth and inhibit apoptosis in neuronal and HL-60 cells 159
Overexpression of cyclin D1 and interaction between p27(Kip1) and tumour thickness predict lymph node metastases occurrence in lower lip squamous cell carcinoma 157
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. 156
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma 155
I tumori della mammella e/o dell’ovaio di tipo eredofamiliare: strategie di prevenzione nelle donne ad alto rischio 155
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. 154
Clinical presentation and treatment of gastrointestinal stromal tumors. 151
Havep53 gene mutations and protein expression a different biological significance in colorectal cancer? 151
A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers 144
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers 144
Emotional expression and coping style in female breast cancer. 144
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. 144
Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. 144
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale 143
BRAFV600E Mutation and p27kip1 Expression in Papillary Carcinomas of the Thyroid ≤1 cm and Their Paired Lymph Node Metastases 143
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. 143
Ductal lavage: a way of carefully tracing the breast-secreting duct 142
Ductal lavage: a valid method of risk assessment and of early diagnosis in breast cancer. 141
A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy 141
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers 138
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells 137
miR-20b Modulates VEGF Expression by Targeting HIF-1a and STAT3 in MCF-7 Breast Cancer Cells 136
Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications 134
TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome 131
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan 128
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 127
ELF regimen in advanced gastrointestinal malignancies: An analysis of its clinical effectiveness and toxicity 123
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? 122
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. 122
Antiproliferative Agents That Interfere with the Cell Cycle at the G(1)-->S Transition: Further Development and Characterization of a Small Library of Stilbene-Derived Compounds 120
Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia 120
A case of squamocellular uterine cervix carcinoma metastatic to the skin with enterocutaneous fistula. 119
Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases 119
Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. 118
Carcinoma squamocellulare del pene localmente avanzato: associazione tra risposta clinica e modificazione dei livelli di ferritina sierica. 117
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer 113
A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma 107
Alexithymia and coping style in women going to visit in a breast cancer center. 103
Ductal Lavage: a valid method of risk assessment and of early diagnosis in breast cance 103
“Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey” 101
Bortezomib: a new pro-apoptotic agent in cancer treatment. 101
Haemopoietic effects of 7 alpha, 17 beta Dimethyltestosterone 100
Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. 99
Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients 99
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. 99
Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II study 99
Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas 99
Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: Clinical implications 99
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. 98
Ondasetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting. Results of a prospective randomized trial 98
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). 97
PML down-regulation in soft tissue sarcomas 97
Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience. 97
Effetti antileucemici di due stilbeni identificati in uve provenienti da vigneti affetti da peronospora e Botrytis cinerea 92
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. 91
A phase II study of capecitabine oxaliplatin chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes 89
Studio di phase II: Docetaxel settimanale come seconda linea chemioterapia nel carcinoma prostatico avanzato. 88
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation 87
Effects of Propolis in cancer cells 85
Emergenze metaboliche 85
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. 85
PML down-regulation in soft tissue sarcomas. 85
Studio del pattern di distribuzione dell'Activina A nel siero di pazienti con metastasi ossee da carcinoma prostatico in trattamento con acido zoledronico 84
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER 80
Alexithymia and copyng style in women going to visit in a breast cancer center 80
Cathepsin D, B and L circulating levels as prognostic markers of malignant progression 79
“Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer:the IGCS-COL multicentre, randomised, phase III study” 78
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. 78
“Effects of combretastatin analogues on leukemic cell lines and normal hemopoietic cells” 77
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study 77
Clinical guidelines for the management of gastrointestinal stromal tumors 76
Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation 76
Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 75
A phase II study of Oxaliplatin Capecitabine chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes 75
Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. 74
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. 71
Lysosomal alterations in heart and liver of mice treated with doxorubicin 71
Ras family genes: An interesting link between cell cycle and cancer 71
Il polimorfismo S128R dell’E-Selectina: analisi genotipica e caratterizzazione funzionale nell’interazione cellule tumorale-endotelio. 70
Pegylated Liposomal Doxorubicin and weekly paclitaxel as first line treatment in metastatic breast cancer 70
Epirubicina (EPI ) e Docetaxel (DOC ) come chemioterapia primaria ( C P ) nel trattamento del carcinoma mammario localmente avanzato ( CMLA ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 69
Gists eredo familiari e pediatrici: aspetti biomolecolari e clinici. 69
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer 69
Totale 12.209
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.116
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.116
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019568 0 0 0 0 0 0 0 0 0 0 293 275
2019/20203.362 368 114 215 289 393 419 381 208 359 192 281 143
2020/20212.328 79 175 90 483 322 81 176 114 233 164 175 236
2021/20221.817 77 437 21 91 93 52 103 86 237 223 91 306
2022/20232.341 258 446 43 250 240 370 177 171 256 15 85 30
2023/2024916 34 149 86 91 68 214 114 110 5 31 14 0
Totale 14.789